This Newly Spun Out Company Trades at Massive Discount to Cash
Insights - Mural Oncology (MURA) is a recent spinout from Alkermes’ (ALKS) oncology division. MURA trades at a 78% discount to its cash balance. Yes, you read … Continue Reading
PremiumInsights - Mural Oncology (MURA) is a recent spinout from Alkermes’ (ALKS) oncology division. MURA trades at a 78% discount to its cash balance. Yes, you read … Continue Reading
PremiumInterviews - PropThink interviewed Jordan Plews, PhD. co-Founder and CEO of Elevai Labs. Dr. Plews completed his postdoctoral and business school training at Stanford University after completing … Continue Reading
Read nowInsights - Medtronic called off its plans to buy EOFlow, a company making an insulin patch-pump that is embroiled in a patent dispute with Insulet (PODD). In May 2023, … Continue Reading
PremiumResearch - The big news in obesity last week was that Pfizer’s Phase 2b data for twice-oral danuglipron flopped. Pfizer’s drug had high discontinuation as a result of high … Continue Reading
Read nowInterviews - TRANSCRIPTParticipants Amelia Tower, KOL Adrian Mendes, Perimeter Medical CEO Deniel Mero, PropThink Editor PropThink Good afternoon everyone, welcome to PropThink’s Digital Conference. My name is … Continue Reading
Read nowResearch - Drug pricing in the US is not a straightforward process. For the most part, this is done by design. Politicians and media have put the … Continue Reading
Read nowInsights - With Thanksgiving weekend here, food is atop the mind of all Americans. We thought it only appropriate to give an update on the obesity field. … Continue Reading
Read now